Atika Capital Management’s Pliant Therapeutics PLRX Stock Holding History

Atika Capital Management’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-109,190	Closed	-$2.9M	–	99
2023 Q1	$2.9M	Buy	+109,190	New	+$3.11M	0.43%	59
2022 Q4	–	Sell	-195,000	Closed	-$4.07M	–	101
2022 Q3	$4.07M	Buy	+195,000	New	+$3.73M	0.35%	75

Other funds holding PLRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Atika Capital Management's PLRX Position: Q2 2023 in Review

Atika Capital Management sold out of Pliant Therapeutics (PLRX) in Q2 2023, closing a stake of 109,190 shares — an estimated $2.9M sold.

Atika Capital Management first reported a position in PLRX in Q3 2022 and held it in 2 quarters. The position peaked at $4.07M in Q3 2022. 144 funds tracked by Wall St. Rank hold PLRX as of Q2 2023.

Atika Capital Management reported no remaining Pliant Therapeutics position as of Q2 2023 after selling out during the quarter.
Atika Capital Management sold 109,190 Pliant Therapeutics shares in Q2 2023, an estimated $2.9M.
Atika Capital Management first reported a position in Pliant Therapeutics in Q3 2022 and held it in 2 quarters.
Atika Capital Management's Pliant Therapeutics position peaked at $4.07M in Q3 2022.
144 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2023.

Based on Atika Capital Management's 13F filing for Q2 2023, filed 11 Aug 2023.